Product intelligence · HS 293790 · 2024 data

Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in 2937

Global exports of hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in 2937 totalled $438,447,153 in 2024, a -5.3% change from the previous year. Traded by 88 countries across 1,446 bilateral corridors, with demand from 168 importing markets. The long-term trend is declining.

Data: OECD BIMTS · Coverage: 19952024 · Updated: 2026-07-17

Global trade

$438.4M

-5.3% YoY

3Y / 5Y CAGR

-7.2%

5Y: -10.1%

Supply structure

Diversified

HHI 0.131

Volatility

Low

Score 21/100

1.

Market movement

In 2024, hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in 2937 trade exhibited significant decline, with global flows reaching $438,447,153 and a three-year compound annual growth rate of -7.2% (five-year: -10.1%). The all-time peak of $1,752,760,760 was recorded in 2004; the current level is 75% below that high-water mark.

Over the 30-year observation window (19952024), 45% of years recorded positive growth, indicating significant cyclicality with frequent contractions. Trend momentum is decelerating (-4.4% acceleration).

2.

Supply & demand structure

The supply side is diversified (Herfindahl-Hirschman Index 0.131). The three largest exporters — France ($88.8M), Ireland ($79.5M), and China ($71.6M) — collectively dominate supply flows. The leading exporter has grown at -14.1% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.139). The three largest import markets are United States ($129.8M), France ($78.8M), and India ($37.7M). The largest importing market sources from 29 different supplying countries.

The dominant trade corridor is France → United States at $76.6M, representing 59.0% of the importer's total demand.

3.

Risk profile & trade outlook

The volatility score for hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in 2937 is 21 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, contracting demand signals caution before committing resources. The diversified supply landscape means many competitors but also multiple entry points and buyer relationships to target.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.

Historical evidence

Annual trade value 19952024

Peak: $1,752,760,760 in 2004. Currently 75% below peak.

YearGlobal trade (USD)YoY growth
2015$525,471,228-9.7%
2016$626,507,541+19.2%
2017$577,330,666-7.8%
2018$664,624,699+15.1%
2019$747,902,159+12.5%
2020$739,854,939-1.1%
2021$549,108,203-25.8%
2022$685,200,146+24.8%
2023$462,859,975-32.4%
2024$438,447,153-5.3%

Top exporting countries

Ranked by export value of hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in 2937 in 2024.

View all 88 exporters →

Top importing markets

Largest import destinations for hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in 2937.

View all 168 markets →

Leading trade corridors

Largest bilateral export flows for hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in 2937, ranked by value. Click any country to view its full profile.

#ExporterImporterValue 20243Y CAGR
1FranceUnited States$76.6M-15.1%
2IrelandFrance$73.3M+4.7%
3ChinaUnited States$29.3M-5.9%
4IndiaRussia$27.1M+59.0%
5GermanyChina$23.9M+858.3%
6ChinaIndia$20.3M-2.2%
7GermanyIndia$6.9M+6.6%
8GermanyUnited States$6.5M-22.4%

Showing top 8 of 10 corridors with available data for 2024.

Go deeper

Get the full intelligence picture

Interactive charts, AI-powered opportunity scoring, competitor benchmarking, and real-time alerts for hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis: derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones, n.e.c. in 2937. Free to start — no credit card required.

Sources, definitions & methodology

Data source

OECD Bilateral International Merchandise Trade Statistics (BIMTS). Aggregated from 312M+ reported trade records across 200+ countries and 5,300+ HS6 product codes. Coverage: 19952024.

Key indicators

HHI (Herfindahl-Hirschman Index): market concentration, 0 = fully diversified, 1 = single player. CAGR: compound annual growth rate over a stated period. Volatility score: trade value variability, 0–100 scale.

How this page is made

All statistical content on this page is data-driven, composed programmatically from live OECD trade records. No generic AI-generated prose is used. Analytical paragraphs combine real data points with factual interpretation. This page was last refreshed on 2026-07-17.